
    
      The time of onset and duration of local and systemic solicited reactions will be assessed and
      reported. Unsolicited adverse events (including serious adverse events) will be collected and
      categorized throughout the study period.

      Antibody levels will be evaluated by hemagglutination inhibition (HI) assay from sera
      obtained pre-vaccination (Day 0) and 21 days post-vaccination, for antigens from the
      2004-2005 influenza virus strains: A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2),
      and B/Jiangsu/10/2003.
    
  